Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 800 · Balance 2,503 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Row 2 · 2026-08-10 · Sale · Disposed 800 · Balance 1,703 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $376.69 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 800 · Balance 0 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F2: The stock option vested in three equal annual installments, commencing one year after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
F2: The stock option vested in three equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001681643-26-000006 · edgardoc.xml · derivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F2 · derivative.exercise_date: The stock option vested in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $800.00 | $640,000.00 |
DisclosureSEC source: 0001681643-26-000006 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,703 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 800 | $376.69 | $301,352.00 |
DisclosureSEC source: 0001681643-26-000006 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,638 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · derivative · entry 13 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 1,638 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F10 · derivative.exercise_date: The stock option vested in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $790.00 | $3,160.00 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 12 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,703 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 56 | $785.61 | $43,994.16 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 11 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,707 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F9 · price: Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 160 | $784.45 | $125,512.00 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 10 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,763 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F8 · price: Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 220 | $783.29 | $172,323.80 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 9 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,923 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F7 · price: Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 298 | $782.10 | $233,065.80 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 8 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,143 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F6 · price: Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 209 | $781.28 | $163,287.52 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 7 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,441 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F5 · price: Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 331 | $780.45 | $258,328.95 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 6 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,650 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F4 · price: Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 208 | $779.55 | $162,146.40 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 5 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,981 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F3 · price: Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 53 | $778.47 | $41,258.91 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 4 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,189 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F2 · price: Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $775.50 | $38,775.00 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,242 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 49 | $774.68 | $37,959.32 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,292 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:55 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,638 | $376.69 | $617,018.22 |
DisclosureSEC source: 0001681643-26-000004 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001681643-26-000002 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001681643-26-000002 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,703 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000009 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000009 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,548 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000028 · edgardoc.xml · derivative · entry 5 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F4 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,117 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001968202-24-000028 · edgardoc.xml · derivative · entry 4 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,117 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023. F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000028 · edgardoc.xml · nonDerivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F2 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,117 | $900.00 | $1,005,300.00 |
DisclosureSEC source: 0001968202-24-000028 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,117 | $391.92 | $437,774.64 |
DisclosureSEC source: 0001968202-24-000028 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001968202-23-000037 · edgardoc.xml · derivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,117 Underlying: Common Stock · 1,000 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $850.00 | $850,000.00 |
DisclosureSEC source: 0001968202-23-000037 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $391.92 | $391,920.00 |
DisclosureSEC source: 0001968202-23-000037 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000013 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000013 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001708138-22-000024 · edgardoc.xml · derivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,117 Underlying: Common Stock · 2,000 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $675.00 | $1,350,000.00 |
DisclosureSEC source: 0001708138-22-000024 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $391.92 | $783,840.00 |
DisclosureSEC source: 0001708138-22-000024 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:24 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001883850-22-000009 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:24 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000009 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 998 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001708138-21-000081 · edgardoc.xml · derivative · entry 6 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,117 Underlying: Common Stock · 998 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 998 | $650.00 | $648,700.00 |
DisclosureSEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 4 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 998 | $391.92 | $391,136.16 |
DisclosureSEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001708138-21-000081 · edgardoc.xml · derivative · entry 5 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,115 Underlying: Common Stock · 2 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $651.10 | $1,302.20 |
DisclosureSEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2 | $391.92 | $783.84 |
DisclosureSEC source: 0001708138-21-000081 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001708138-21-000010 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000010 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,706 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001237899-20-000028 · edgardoc.xml · derivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,117 Underlying: Common Stock · 1,706 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,706 | $650.00 | $1,108,900.00 |
DisclosureSEC source: 0001237899-20-000028 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,706 | $391.92 | $668,615.52 |
DisclosureSEC source: 0001237899-20-000028 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,706 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · derivative · entry 15 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,823 Underlying: Common Stock · 1,706 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,706 | $625.00 | $1,066,250.00 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 13 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,706 | $391.92 | $668,615.52 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 12 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,706 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · derivative · entry 14 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,529 Underlying: Common Stock · 1,706 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.